CIMAVAX-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer. It was developed in Cuba by the Center for Molecular Immunology. The Cimavax vaccine works by creating a protein in the body that primes the immune system to attack a hormone called epidermal growth factor (EGF), a naturally occurring hormone in the body. If someone already has cancer, their body gets rid of cancer cells. In someone who is in remission, or has never had lung cancer, the treatment acts as a vaccine.
A study published in the Journal of Clinical Oncology concludes there is a direct correlation between vaccination and survival. According to the Latin Times, studies show the vaccine could offer high-risk patients an additional 18 years of life. US citizen Mick Phillips has traveled to Cuba via Canada for the last five years for the vaccine. Both Mick and his doctor credit the vaccine for Mick’s continued remission.
In 2015, before President Obama went to Cuba, the governor of New York forged an agreement between the Roswell Park Cancer Institute in Buffalo, NY and Cuba’s Center for Molecular Immunology that allows RPCI to take the drug through testing and trials in the US. In June of this year during the visit of Cuban Health Minister Roberto Tomas Morales Ojeda, the US and Cuba signed an agreement promising to work together in the fight against the Zika virus and cancer. There are also ways to speed ClimaVax through the FDA approval process. The vaccine is in the trial process in the UK, Canada, China and Peru and is in the process of approval in Argentina, Brazil, Colombia, and Paraguay.
Our strategy focuses on enabling our clients to recruit the right people for the structure in which they will perform. Please contact us to learn more about our expertise in Executive Search for Commercial Leadership positions in Medical Device and Biotechnology; including Marketing, Strategy, Sales Leadership, Training, Development, etc. We look forward to the opportunity to help you consistently improve your performance and your business!
Follow me on Twitter @PrimeCoreSearch.